POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY

• US 20080248097A1
• Filed: 02/26/2008
• Published: 10/09/2008
• Est. Priority Date: 02/26/2007
• Status: Abandoned Application

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: Bae, Younsoo, Kwon, Glen S., Alani, Adam WG.
• Application Number:
  US12/037,840
• Publication Number:
  US 20080248097A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 47/6907 the form being a microemulsion, nanoemulsion or micelle
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The invention provides block polymers, micelles, and micelle formulations for combination drug therapy. Polyamide block polymers, such as those of formulas I and II are useful, for example, for preparation of mixed drug micelles, including simply mixed micelles, physically mixed micelles, and chemically mixed micelles. The invention further provides methods of treating cancer, and inhibiting and killing cancer cells. Also provided are methods for the preparation of polymer drug conjugates and intermediates for their synthesis.

Claims

1. A block polymer comprising a first block and a second block;

wherein

the first block comprises two or more ethylene glycol segments;

the second block comprises two or more amino acid units derived from aspartic acid, glutamic acid, or a combination of aspartic acid and glutamic acid;

two or more amino acid side chains of the second block are individually covalently linked to therapeutic agents through hydrazide moieties; and

the therapeutic agents comprise at least two different therapeutic agents.

2. The polymer of claim 1 wherein the hydrazide moieties are formed from the condensation of side chain carboxylate moieties of the second block, hydrazine or hydrazine derivatives, and carbonyl moieties of the therapeutic agents or carbonyl moieties of a linking group on the therapeutic agent.

3. The polymer of claim 2 wherein the linking group on the therapeutic agent comprises a C₁-C₂₀ carbon chain, ring, or combination thereof, optionally interrupted by one to eight oxygen atoms, nitrogen atoms, or amide groups and optionally substituted with one to eight oxo groups.

4. The polymer of claim 1 wherein the therapeutic agents comprise drugs that are effective for the treatment of cancer and the therapeutic agents have low water solubility.

5. The polymer of claim 1 wherein the eight or more ethylene glycol segments form a poly(ethylene glycol) chain that has a molecular weight of about 400 to about 30,000 g/mol, the poly(ethylene) glycol chain is straight or branched, and the poly(ethylene glycol) chain terminates with a hydroxyl group, an alkoxy group, a hydroxyl protecting group, or an optionally substituted or protected amino group.

6. The polymer of claim 1 wherein one or more amino acid side chains of the second block are individually covalently linked to therapeutic agents through ester linkages.

7. The polymer of claim 1 wherein the first block and the second block are linked to each other through an amide bond or a linking group.

8. The polymer of claim 1 wherein the molecular weight of the second block is about 500 to about 20,000 g/mol, and the amino acid units are optionally derived from L-amino acids.

9. The polymer of claim 1 wherein greater than about 50% of the amino acid side chains are individually linked to therapeutic agents, and the polymer comprises two, three, or four different types of therapeutic agents.

10. The polymer of claim 9 wherein the different therapeutic agents provide a synergistic therapeutic effect when administered to a cancer patient.

11. The polymer of claim 4 wherein the therapeutic agents comprise aclarubicin, apicidin, bortezomib, benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal, cyclopamine-KAAD, cucurbitacin, dolastatin, doxorubicin, fenritinide, geldanamycin, herbimycin A, 2-methoxyestradiol, paclitaxel, radicicol, rapamycin, triptolide, wortmannin, or a combination thereof.

12. The polymer of claim 11 comprising a first block and a second block;

wherein

the first block comprises about 10 to about 600 ethylene glycol segments;

the second block comprises 5 to about 100 amino acid units derived from aspartic acid, glutamic acid, or a combination of aspartic acid and glutamic acid; and

two or more side chains of the second block are covalently linked to a therapeutic agent through a linker of the formula;

16. A micelle comprising a plurality of polymers of claim 1, wherein the therapeutic agents reside toward the core of the micelle and the ethylene glycol segments of the polymers align toward the corona of the micelle.

13. A polymer comprising formula I:

14. The polymer of claim 13 that has formula II:

15. The polymer of claim 14 wherein the therapeutic agents comprise aclarubicin, apicidin, bortezomib, benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal, cyclopamine-KAAD, cucurbitacin, dolastatin, doxorubicin, fenritinide, geldanamycin, herbimycin A, 2-methoxyestradiol, paclitaxel, radicicol, rapamycin, triptolide, wortmannin, or a combination thereof.

17. A micelle formulation comprising a plurality of block polymers comprising a first block and a second block;

wherein

the first block comprises two or more ethylene glycol segments;

the second block comprises two or more amino acid units derived from aspartic acid, glutamic acid, or a combination of aspartic acid and glutamic acid;

at least one amino acid side chain of the second block is covalently linked to a therapeutic agent through a hydrazide moiety; and

the micelles of the formulation comprise at least two different therapeutic agents.

18. The micelle formulation of claim 17 wherein each individual micelle of the formulation comprises only one type of therapeutic agent.

19. The micelle formulation of claim 17 wherein each individual micelle comprises two or more therapeutic agent and wherein each individual polymer of each micelle comprises only one type of therapeutic agent.

20. A method of inhibiting the growth of cancer cells or killing cancer cells comprising contacting the cells with an effective amount of the micelle formulation of claim 17.

21. A method of treating cancer comprising administering to a patient in need of cancer treatment a therapeutically effective amount of the micelle formulation of claim 17.

22. The method of claim 21 wherein cancer treatment comprises delivering two or more drugs to a tumor, and wherein the ratio of drug types delivered to the tumor is determined by controlling the ratio of polymers individually comprising different therapeutic agents that are used to prepare the micelles of the micelle formulation.

23. A method of delivering a therapeutic agent to an organ or a tumor comprising administering the micelle formulation of claim 17 to the organ or cell, wherein the polymers of the micelles hydrolyze to release the therapeutic agents upon encountering a pH of less than about 7.